- Biopharma News
AGC Biologics and Rocket Pharma expand LVV manufacturing partnership20 Apr 2021
The expanded agreement will ensure Rocket Pharma's supply of lentiviral vectors across its pipeline
Global biopharmaceutical contract development and manufacturing organisation (CDMO) AGC Biologics says it has expanded its partnership with Rocket Pharmaceuticals to manufacture lentiviral vectors for the company across its entire LVV pipeline.
AGC Biologics will manufacture LVVs at its Center of Excellence for Cell and Gene Therapy services in Milan, Italy, using the 48L Cell Factory Systems and iCellis 500 bioreactor platforms.
AGC Biologics said it has developed a reproducible, high quality and quantity process for the industrial-scale production of LVV in response to customer needs and market demand.
"This process allows for the successful scale of LVV manufacture without affecting critical quality attributes (CQA), ultimately improving the commercial viability of LVV-based gene therapies," the CDMO said.
In February, AGC Biologics announced the expansion of its Milan facility, which it had acquired in July 2020 after its takeover of Italian biotech MolMed, and which was the first GMP facility approved in Europe for ex vivo gene therapy manufacturing.
The company expects to complete the expansion in 2022.
Are you a supplier?
Here's what CPhI Online can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation